Existing research indicates that patients with CMS4 subtype exhibit low immune activity, high invasiveness and metastatic potential, prominent stromal component, and gene expression features related to tumor growth and dissemination, such as angiogenesis and TGF-β signaling pathways. This evidence concerns the gene TGFB1 and neoplasm.